M&A Deal Summary

Incannex Healthcare Acquires APIRx Pharmaceutical USA

On March 24, 2022, Incannex Healthcare acquired life science company APIRx Pharmaceutical USA for 93M USD

Acquisition Highlights
  • This is Incannex Healthcare’s 1st transaction in the Life Science sector.
  • This is Incannex Healthcare’s largest (disclosed) transaction.
  • This is Incannex Healthcare’s 1st transaction in the United States.

M&A Deal Summary
Date 2022-03-24
Target APIRx Pharmaceutical USA
Sector Life Science
Buyer(s) Incannex Healthcare
Deal Type Add-on Acquisition
Deal Value 93M USD

Target

APIRx Pharmaceutical USA

United States
APIRx Pharmaceutical USA is an innovative biotechnology company focused on research, development, and production of prescription pharmaceutical cannabinoid medicines. It has twenty-two (22) active clinical and pre-clinical research and development projects utilising proprietary technologies. APIRx Pharmaceutical USA is based in United States.

Search 202,458 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Incannex Healthcare

Sydney, Australia
Category Company
Founded 2001
Sector Life Science
Revenue 2M AUD (2021)
DESCRIPTION

Incannex Healthcare is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of anxiety disorders, obstructive sleep apnoea (OSA), traumatic brain injury (TBI)/concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis and inflammatory bowel disease. Incannex Healthcare was founded in 2001 and is based in Sydney, Australia.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (United States) 1 of 1
Year (2022) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal